HSC Section 6 Nov2016 Green Book

18. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740–749. 19. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011–1021. 20. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultane- ous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004;99:1037–1043. 21. Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refrac- tory gastroesophageal reflux disease, on and off therapy. Clin Gastroen- terol Hepatol 2009;7:743–748. 22. Tutuian R, Mainie I, Agrawal A, et al. Normal values for ambulatory 24- hour combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006;130:A171. 23. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multi- channel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplica- tion. Br J Surg 2006;93:1483–1487. 24. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpreta- tion of symptom indexes in reflux monitoring for refractory gastroesoph- ageal reflux disease. Clin Gastroenterol Hepatol 2011;9:868–874. 25. Vaezi MF, Higginbotham T, Kavitt RT, et al. Do patients report symptoms when they occur? Fundamental consequences for interpretation of am- bulatory reflux monitoring. Gastroenterology 2012;142:S–415. 26. Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. Laryngoscope 2011;121:1902–1909. 27. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100: 283–289. 28. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992;117:977–982. 29. Jones MP, Sloan SS, Rabine JC, Ebert CC, Huang CF, Kahrilas PJ. Hiatal hernia size is the dominant determinant of esophagitis presence and se- verity in gastroesophageal reflux disease. Am J Gastroenterol 2001;96: 1711–1717. 30. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192– 1199. 31. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gas- tro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156–160.

3. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101: 2128–2138. 4. Frye JW, Vaezi MF. Extraesophageal GERD. Gastroenterol Clin North Am 2008;37:845–858, ix. 5. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:2646–2654. 6. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Associ- ation Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392–413, 413 e1–5. 7. Park W, Vaezi MF. Esophageal impedance recording: clinical utility and limitations. Curr Gastroenterol Rep 2005;7:182–189. 8. Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. Nat Clin Pract Gastroenterol Hepatol 2006;3: 210–219. 9. Tutuian R, Castell DO. Review article: complete gastro-oesophageal reflux monitoring—combined pH and impedance. Aliment Pharmacol Ther 2006;24 (suppl 2):27–37. 10. Agrawal A, Castell DO. Clinical importance of impedance measurements. J Clin Gastroenterol 2008;42:579–583. 11. Bredenoord AJ, Tutuian R, Smout AJ, Castell DO. Technology review: esophageal impedance monitoring. Am J Gastroenterol 2007;102: 187–194. 12. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multi- centre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398–1402. 13. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956–1963. 14. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treat- ment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100: 190–200. 15. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastro- esophageal reflux disease. Gastroenterology 2008;135:1383–1391, 91 e1–5. 16. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: pro- spective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope 2005;115: 1230–1238. 17. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesopha- gitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172–180.

Laryngoscope 123: October 2013

Kavitt et al.: The Role of Impedance Monitoring in Extraesophageal Symptoms

144